Ubiquinol-cytochrome c reductase binding protein (UQCRB), a component of the mitochondrial complex III, has been recently implicated in angiogenesis. Targeting mitochondria to balance vascular homeostasis has been widely recognized. However, the effect of UQCRB replenishment by direct delivery remains unknown. To explore the biological function of UQCRB in angiogenesis, a novel protein transduction domain (PTD)-conjugated UQCRB fusion protein was generated. PTD-UQCRB localized to mitochondria as does endogenous UQCRB. Treatment with PTD-UQCRB generated mitochondrial reactive oxygen species (mROS) without cytotoxicity, following hypoxia inducible factor-1α (HIF-1α) stabilization and downstream vascular endothelial growth factor (VEGF) expression. Accordingly, PTD-UQCRB induced angiogenesis in vitro and PTD-UQCRB pro-angiogenic activity was further validated in matrigel plug assay and in cutaneous wound-healing mouse models in vivo. Together, these results demonstrate that UQCRB plays a role in angiogenesis and the developed cell-permeable PTD-UQCRB can be utilized as a pro-angiogenic agent.
Bibliographical noteFunding Information:
This work was partly supported by grants from the National Research Foundation of Korea grant funded by the Korean government (MSIP; 2010-0017984 , 2012M3A9D1054520 ), Translational Research Center for Protein Function Control, NRF ( 2009-0083522 ), Ministry of Health and Welfare ( 0620360-1 ), and Brain Korea 21 Plus Project, Republic of Korea .
© 2015 Elsevier Ireland Ltd.
All Science Journal Classification (ASJC) codes
- Cancer Research